Latest news with #GileadSciencesInc
Yahoo
16 hours ago
- Business
- Yahoo
RBC Capital Lifts Gilead Sciences (GILD) PT to $95 On Insights From a 2022 Patient Survey
Gilead Sciences Inc. (NASDAQ:GILD) is one of the 11 most profitable NASDAQ stocks to buy now. On June 11, RBC Capital increased its price target for Gilead Sciences to $95 from $92, while maintaining a Sector Perform rating. This adjustment is based on insights from a 2022 patient survey, which assessed perceptions of lenacapavir among high-risk individuals on and off PrEP (pre-exposure prophylaxis), especially after phase 3 data release and in anticipation of its potential market launch. The firm's analysis suggests that high clinician engagement, lower-than-expected adherence to oral PrEP medications, and the potential for current PrEP users to switch to lenacapavir could all facilitate growth for Gilead Sciences, even with some cannibalization of its existing product called Descovy. A physician and a patient having a discussion in a hospital about biopharmaceutical medicines. In Q1 2025, Gilead Sciences reported total revenue of $6.67 billion, which was flat year-on-year and missed Street's estimates by 2.1%. Despite the revenue miss, Gilead reconfirmed its full-year revenue guidance at the midpoint of $28.4 billion, which is 1.1% below analysts' estimates. These results were driven by growth in the company's core HIV and liver disease segments, particularly from strong demand for Biktarvy and the ongoing launch of Libdelzi. Gilead Sciences Inc. (NASDAQ:GILD) is a biopharmaceutical company that discovers, develops, and commercializes medicines in the areas of unmet medical need in the US, Europe, and internationally. While we acknowledge the potential of GILD as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the . READ NEXT: and . Disclosure: None. This article is originally published at Insider Monkey.
Yahoo
23-05-2025
- Business
- Yahoo
Gilead (GILD) to Acquire HOOK for $10 million
Gilead Sciences Inc. (NASDAQ:GILD) has announced it will be taking over HOOKIPA Pharma Inc. (NASDAQ:HOOK) for a consideration of $10 million. Gilead Sciences Inc. (NASDAQ:GILD) commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. GILD is only purchasing HOOK's antiviral programs, specifically the 'HB-400' & 'HB-500'. The company first invested $21.25 million in HOOK in 2023, with the aim of advancing its HIV program, i.e., through only the HB-500 program at that time. Gilead Sciences Inc. (NASDAQ:GILD) has also backed a merger between HOOK and Poolberg Pharma, in an attempt to make a stronger clinical-stage biopharmaceutical company focused on next-generation immunotherapies for cancer and other serious diseases HOOKIPA Pharma is a clinical-stage biopharmaceutical company that develops immunotherapies targeting infectious diseases based on its proprietary arenavirus platform. HOOK has a current market capitalization of over $19 million. Regarding the terms and timelines of the financing, the agreement will take place in three milestones. The first $3m will be paid out at the close of the deal. After that, a three-phase transfer plan will make HOOK eligible to receive $7m. The first phase will give HOOK access to the first tranche of $3m, and the remaining two phases will see HOOK receive $2 million for each phase. The deal is currently awaiting approval from the shareholders of HOOK. The company's share price peaked at $1.75 on May 21, 2025, and closed at $1.52 at the end of trading. While we acknowledge the potential of GILD, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than GILD and that has 100x upside potential, check out our report about this cheapest AI stock. READ NEXT: and Disclosure: None. Sign in to access your portfolio
Yahoo
20-05-2025
- Business
- Yahoo
Stock Market News for May 20, 2025
U.S. stock markets closed higher on Monday after a choppy session. Market participants remained concerned regarding downgrade of the U.S. sovereign credit rating. On the other hand, positive developments on the trade and tariff related front bolstered investors' sentiment. All three major stock indexes ended in positive territory. The Dow Jones Industrial Average (DJI) rose 0.3% or 137.33 points to close at 42,792.07. At intraday low, the blue-chip index was down by 307 points. Notably, 16 components of the 30-stock index ended in positive territory and 14 finished in negative zone. The tech-heavy Nasdaq Composite finished at 19,215.46, rising 0.02% due to strong performance of bigwigs. The major gainer of the tech-laden index was however Gilead Sciences Inc. GILD. The stock price of the biotech firm was up 3.6%. Gilead Sciences currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. The S&P 500 was up by 5.22 points to finish at 5,963.60. The benchmark posted a six-day winning run. Eight out of 10 broad sectors of the broad-market index ended in positive territory and three in negative zone. The Health Care Select Sector SPDR (XLV) rose 1%. On the other hand, the Energy Select Sector SPDR (XLE) fell 1.3%. The fear-gauge CBOE Volatility Index (VIX) was up 5.2% to 18.14. A total of 19.41 billion shares were traded on Monday, higher than the last 20-session average of 17.34 billion. Decliners outnumbered advancers on the NYSE by a 1.01-to-1 ratio. On Nasdaq, a 1.3-to-1 ratio favored declining issues. On May 16, after the closing bell, Moody's Investor Services downgraded the U.S. sovereign credit rating by one notch to Aa1 from Aaa citing the growing burden of financing the federal government's outstanding budget deficit of a mammoth $36 trillion and the rising cost of rolling over existing debt under the high-interest rate regime. According to the rating agency, "Successive US administrations and Congress have failed to agree on measures to reverse the trend of large annual fiscal deficits and growing interest costs.' The rating agency changed its outlook on the United States to "stable" from "negative." Following the development, the yield on the long-term U.S. 30-Year Treasury Note spiked more than 5% and the yield on the benchmark 10-Year U.S. Treasury Note climbed to 4.5%. The 10-year yield is closely link to the mortgage rate. After two days of high-level negotiations, the United States and China have decided to for a 90-day pause of tariff implementations. On May 12, the United States and China agreed in a discussion in Switzerland to reach a temporary agreement that 'reciprocal' tariffs between both countries will be cut from 125% to 10%. Meanwhile, United States' 20% tariffs on Chinese imports relating to fentanyl will remain intact, meaning total tariffs on China will be 30%. U.S. stock markets have faced massive volatility ever since President Donald Trump imposed a 10% baseline tariff on each and every country with which it trades. Tariff rates were much higher for several major trading partners of the United States. The Conference Board reported that the U.S. leading indicator fell by 1% in April compared with the consensus estimate of a decline of 0.9%. The metric for March was revised downward to a drop of 0.8% from a decline of 0.7% reported earlier. The composite index of leading indicators, which is derived from 10 leading indicators, signals the turning points in the economy and forecast economic cycles. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Gilead Sciences, Inc. (GILD) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
07-05-2025
- Health
- Business Wire
Final Data From the Phase 3 MYR301 Study Demonstrated Longer Treatment With Bulevirtide Was Associated With Sustaining Undetectability After Stopping Treatment
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences Inc. (Nasdaq: GILD) today announced final results from the pivotal Phase 3 MYR301 study revealing that 36% (23 out of 64) of adults living with chronic hepatitis delta virus (HDV) treated with the first-in-class entry inhibitor bulevirtide at either a 2 mg or 10 mg dose maintained virologic suppression for almost two years after stopping treatment after achieving undetectable HDV RNA at end of treatment (EOT). In participants who sustained undetectability for one year after end of therapy, no relapses occurred in the second year of follow-up. In addition, sustained post-treatment undetectable HDV RNA was more frequent in participants with longer on-treatment HDV RNA undetectability at end of treatment: 90% (9/10) of those who had HDV RNA undetectability for ≥ 96 weeks at end of treatment remained HDV undetectable off-treatment. These new data, presented at the European Association for the Study of the Liver (EASL) Congress 2025, show the potential value of bulevirtide monotherapy for some adults living with chronic HDV, even after treatment has ended. 'HDV is the most severe form of viral hepatitis with more rapid progression towards liver cancer and liver-related death. Previous data have demonstrated the potential of bulevirtide as a safe and effective treatment option and, as EASL and the European Medicines Agency guidelines recommend, continued treatment is encouraged as long as people are experiencing a clinical benefit,' said Professor Heiner Wedemeyer, Head and Chair of the Department of Gastroenterology, Hepatology, Infectious Diseases and Endocrinology at Hannover Medical School. 'With today's results, we're now seeing the potential of bulevirtide to maintain virologic suppression and normalize markers of liver inflammation for a subset of people living with HDV, demonstrating a durable response, even after treatment cessation.' The findings (LBO-004) build on data, presented at The Liver Meeting ® 2024, hosted by the American Association for the Study of Liver Diseases (AASLD), from MYR301 which demonstrated a subset of participants treated with bulevirtide monotherapy had undetectable HDV RNA 48 weeks after stopping treatment. Today's presentation adds further insight by not only showing the durability of response post-treatment, but that sustained undetectability was more frequent in people with longer, on-treatment HDV RNA undetectability at the time of bulevirtide discontinuation. Furthermore, post-treatment hepatic serious adverse events (SAEs) were reported in 14% (20/142) of participants but were resolved in 85% (17/20) of these participants, most of whom restarted bulevirtide therapy. 'At Gilead, we are committed to advancing research and exploring the full potential of bulevirtide as a monotherapy, in combination, and at different doses, to help improve outcomes for people living with chronic HDV,' said Anu Osinusi, Vice President, Clinical Research for Hepatitis, Respiratory and Emerging Viruses at Gilead. 'Previous results from MYR301 demonstrated the potential benefits of long-term treatment with bulevirtide. With this new data, we now have valuable insight into the durability of the response even after treatment has ended.' HDV affects an estimated 4.5% of people living with chronic hepatitis B (HBV), with an estimated global prevalence of 12 million people. Bulevirtide 2 mg remains the only approved treatment for adults with chronic HDV and compensated liver disease in the European Economic Area (EEA), the UK, Switzerland and Australia and is not approved in the U.S. or elsewhere. Bulevirtide 10 mg is an investigational product and is not approved anywhere. For more information on the EASL Congress 2025 and Gilead's presentations, please visit the congress website. Marketing Authorization In July 2023, the European Commission (EC) granted full Marketing Authorization (MA) for Hepcludex ® (bulevirtide) 2 mg for the treatment of adults with chronic HDV and compensated liver disease. Bulevirtide was initially granted a conditional MA from the EC in July 2020 to provide people living with HDV urgent access to treatment. Bulevirtide's conditional MA license in the UK was converted to a full MA in August 2023, and a full MA was granted in Switzerland in February 2024. In regions where bulevirtide is not approved, including the U.S., bulevirtide 2 mg is an investigational product. In these regions, health authorities have not established the safety and efficacy of bulevirtide. Bulevirtide 10 mg is an investigational product and is not approved anywhere globally. About MYR301 MYR301 is a Phase 3 clinical trial evaluating the long-term efficacy and safety of bulevirtide in 150 people living with chronic HDV randomly allocated to treatment with bulevirtide 2 mg once daily (n=49), 10 mg once daily (n=50) or no antiviral treatment (delayed treatment, n=51). Primary efficacy and safety data was assessed at Week 48. After Week 48, participants in the delayed treatment group of the study were switched to bulevirtide 10 mg once daily for an additional 96 weeks. The total duration of treatment across all groups in the study is 144 weeks. The primary endpoint, combined response, is defined as an undetectable HDV RNA or ≥2log10 IU/ml decline from baseline and ALT normalization at Week 48. Secondary endpoints at Week 48 include undetectable HDV RNA (key secondary endpoint), ALT normalization, and a change from baseline in liver stiffness measured by transient elastography. About Gilead Sciences in Liver Disease For decades, Gilead has pioneered the way forward to improve the lives of people living with liver disease around the world. The company has helped to transform hepatitis C from a chronic condition into a curable condition. For individuals living with hepatitis B or hepatitis delta (HDV), Gilead's focus on advancing medicines drives hope that today's research will turn into tomorrow's cures. Beyond viral hepatitis, Gilead is working to deliver advanced treatments for people living with primary biliary cholangitis. The commitment of Gilead does not stop there. Through ground-breaking science and collaborative partnerships, the company strives to create healthier futures for everyone living with liver disease. Gilead remains devoted to a future without liver disease. About Gilead Sciences Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. The company is committed to advancing innovative medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis, COVID-19, cancer and inflammation. Gilead operates in more than 35 countries worldwide, with headquarters in Foster City, California. Forward-Looking Statements This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks, uncertainties and other factors, including Gilead's ability to initiate, progress or complete clinical trials or studies within currently anticipated timelines or at all, and the possibility of unfavorable results from ongoing or additional clinical trials or studies, including those involving bulevirtide; uncertainties relating to regulatory applications and related filing and approval timelines, including additional pending and potential applications for bulevirtide; and the risk that any such approvals, if granted, may be subject to significant limitations on use; the risk that physicians may not see the benefits of prescribing bulevirtide for the treatment of HDV; and any assumptions underlying any of the foregoing. These and other risks, uncertainties and factors are described in detail in Gilead's Quarterly Report on Form 10-Q for the quarter ended March 31, 2025, as filed with the U.S. Securities and Exchange Commission. These risks, uncertainties and other factors could cause actual results to differ materially from those referred to in the forward-looking statements. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. The reader is cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties and is cautioned not to place undue reliance on these forward-looking statements. All forward-looking statements are based on information currently available to Gilead, and Gilead assumes no obligation and disclaims any intent to update any such forward-looking statements. Hepcludex®, Gilead and the Gilead logo are registered trademarks of Gilead Sciences, Inc., or its related companies. follow Gilead on X/Twitter (@Gilead Sciences) and LinkedIn (@Gilead-Sciences).
Bloomberg
29-04-2025
- Health
- Bloomberg
Gilead Reaches $202 Million Settlement Over Payments to Doctors
Gilead Sciences Inc. reached a $202 settlement with the US to resolve claims that it paid doctors and gave them meals and travel expenses for events to get them to prescribe its drugs. Federal prosecutors in Manhattan alleged that Gilead conducted programs from January 2011 to November 2017 to promote and increase sales of its drugs to treat the AIDS virus. The events were supposed to be purely educational, with modest meals.
